Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 7Plasma cell 2NET 2Endocrine 2Lymphoid 1Gastrointestinal 1

Conditions

Multiple Myeloma 2Neoplasms 1

Interventions

Dexamethasone 178Bortezomib 100Lenalidomide 90daratumumab 47Melphalan 46Thalidomide 44pomalidomide 43Cyclophosphamide 38Calcium Dobesilate 30carfilzomib 29Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 14isatuximab 12ixazomib 11Granulocyte Colony-Stimulating Factor 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10dexamethasone acetate 9belantamab mafodotin 9Zoledronic Acid 8selinexor 7Epoetin Alfa 7fludarabine 6Etoposide 6dexamethasone 21-phosphate 5auricularum 5Mycophenolic Acid 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Introns × Plasma cell × Clear all
NCT00083551 2015-11-23

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

University of Arkansas

Phase 3 Completed
668 enrolled 7 charts
Plasma cell

Multiple Myeloma, Neoplasms

NCT00002556 2013-05-31

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Completed
312 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡